We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine.
- Authors
Figgins, Bradley; Primeaux, Brian; Shank, Brandon R; Chen, Sheree E; Weber, Donna M; Lu, Huifang
- Abstract
Introduction: Cyclophosphamide is a nitrogen mustard alkylator employed in the treatment of many malignancies and autoimmune disorders. Despite reports of cyclophosphamide hypersensitivity ranging from rash to anaphylaxis, no cases of desensitization have been reported in the oncologic setting. Case report: We report a cyclophosphamide desensitization protocol used for two patients who experienced severe hypersensitivity to bendamustine, a structurally related drug with potential cross immunogenicity. Management and outcome: An interdisciplinary approach including immunologist, oncologist, and clinical pharmacists resulted in the development of a multi-step desensitization protocol for cyclophosphamide. The desensitization protocol described enabled the safe administration of cyclophosphamide for the two patients with limited treatment alternatives. Discussion: To the authors' knowledge, this is the first report of cyclophosphamide desensitization in the oncologic setting. Two patients with advanced hematologic malignancies were able to receive cyclophosphamide with minimal adverse effects, despite experiencing previous severe hypersensitivity to another nitrogen mustard analogue.
- Subjects
ALLERGY desensitization; DRUG allergy; MOLECULAR structure; NITROGEN mustards; ONCOLOGISTS; SEVERITY of illness index; CYCLOPHOSPHAMIDE; HEMATOLOGIC malignancies
- Publication
Journal of Oncology Pharmacy Practice, 2020, Vol 26, Issue 4, p982
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/1078155219867127